Johnson & Johnson (NYSE:JNJ) Shares Sold by BTR Capital Management Inc.

BTR Capital Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,757 shares of the company’s stock after selling 400 shares during the period. BTR Capital Management Inc.’s holdings in Johnson & Johnson were worth $7,412,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $26,000. RE Dickinson Investment Advisors LLC increased its position in Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the period. Advanced Research Investment Solutions LLC increased its position in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the period. Professional Financial Advisors LLC increased its position in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $38,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Stock Down 0.8 %

Johnson & Johnson stock opened at $164.97 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a market cap of $433.74 billion, a PE ratio of 24.01, a price-to-earnings-growth ratio of 2.97 and a beta of 0.61. The stock’s 50 day moving average price is $168.71 and its 200 day moving average price is $174.30.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.48 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 10.7 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.74%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson announced that its board has approved a share buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JNJ. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. SVB Leerink dropped their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley dropped their target price on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Finally, Citigroup dropped their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.